Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.49 |
| ▸ | PLD1 | Q13393 | 3/20 | 0.49 |
| ▸ | PLD2 | O14939 | 2/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713418 | 0.93 | PLD2 (0.51) | DRD2HTR1AADRA2AHTR2ASLC6A4 | |
| SCHEMBL4897490 | 0.92 | OPRM1 (0.52) | DRD2HTR1AADRA2AHTR2ASLC6A4 | |
| SCHEMBL4711335 | 0.90 | OPRM1 (0.58) | DRD2HTR1AADRA2AHTR2ASLC6A4 | |
| SCHEMBL4713593 | 0.83 | AVPR1A (0.45) | DRD2HTR1AADRA2AHTR2ASLC6A4 | |
| SCHEMBL4711275 | 0.76 | DRD2 (0.46) | DRD2SLC6A4CTSSHSD11B1 | |
| SCHEMBL10316252 | 0.76 | DRD2 (0.76) | DRD2HTR1AADRA2AHTR2ASLC6A4 | |
| SCHEMBL12575055 | 0.76 | DRD2 (0.52) | DRD2HTR1AADRA2AHTR2ASLC6A4 | |
| SCHEMBL26666399 | 0.75 | DRD2 (0.70) | DRD2HTR1AADRA2AHTR2ASLC6A4 | |
| SCHEMBL4444487 | 0.74 | CHRM1 (0.72) | DRD2HTR1AADRA2AHTR2ASLC6A4 | |
| SCHEMBL4903299 | 0.73 | CCR5 (0.48) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | claimed |
| EP-1877399-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2008-01-16 | — | — | EP | claimed |
| WO-2006114706-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | claimed |
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188478-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | DRD2 353/4885HTR1A 101/4885ADRA2A 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.